The Best AI Stock to Own in the World Today is Trading for Just $25

“Titan of Tech” Bets Big on Tiny AI Company He’s made as much as 3,250,000% in just three years on companies like Facebook, Airbnb, and PayPal… But our research shows his latest investment could be his most successful venture yet.

James C. Hamilton net worth and biography

James Hamilton Biography and Net Worth

Sr. VP of Discovery & Translational Medicine of Arrowhead Pharmaceuticals

Dr. James C. Hamilton is the Sr. VP of Discovery & Translational Medicine at Arrowhead Pharmaceuticals.

What is James C. Hamilton's net worth?: The estimated net worth of James C. Hamilton is at least $4.66 million as of January 12th, 2024. Dr. Hamilton owns 210,851 shares of Arrowhead Pharmaceuticals stock worth more than $4,664,024 as of April 27th. This net worth estimate does not reflect any other assets that Dr. Hamilton may own. Additionally, Dr. Hamilton receives a salary of $762,140.00 as Sr. VP of Discovery & Translational Medicine at Arrowhead Pharmaceuticals. Learn More about James C. Hamilton's net worth.
How old is James C. Hamilton?: Dr. Hamilton is currently 46 years old. There are 6 older executives and no younger executives at Arrowhead Pharmaceuticals. The oldest executive at Arrowhead Pharmaceuticals is Dr. Bruce D. Given M.D., Chief Medical Scientist, who is 70 years old. Learn More on James C. Hamilton's age.
What is James C. Hamilton's salary?: As the Sr. VP of Discovery & Translational Medicine of Arrowhead Pharmaceuticals, Inc., Dr. Hamilton earns $762,140.00 per year. There are 3 executives that earn more than Dr. Hamilton. The highest earning executive at Arrowhead Pharmaceuticals is Dr. Christopher R. Anzalone Ph.D., CEO, President & Director, who commands a salary of $1,600,000.00 per year. Learn More on James C. Hamilton's salary.
How do I contact James C. Hamilton?: The corporate mailing address for Dr. Hamilton and other Arrowhead Pharmaceuticals executives is 177 E. Colorado Blvd Suite 700, Pasadena CA, 91105. Arrowhead Pharmaceuticals can also be reached via phone at (626) 304-3400 and via email at [email protected]. Learn More on James C. Hamilton's contact information.
Has James C. Hamilton been buying or selling shares of Arrowhead Pharmaceuticals?: James C. Hamilton has not been actively trading shares of Arrowhead Pharmaceuticals during the last ninety days. Most recently, James C. Hamilton sold 7,940 shares of the business's stock in a transaction on Friday, January 12th. The shares were sold at an average price of $36.89, for a transaction totalling $292,906.60. Following the completion of the sale, the insider now directly owns 210,851 shares of the company's stock, valued at $7,778,293.39. Learn More on James C. Hamilton's trading history.
Who are Arrowhead Pharmaceuticals' active insiders?: Arrowhead Pharmaceuticals' insider roster includes Christopher Anzalone (CEO), Marianne De Backer (Director), Mauro Ferrari (Director), Douglass Given (Director), James Hamilton (Sr. VP of Discovery & Translational Medicine), James Hassard (Insider), Kenneth Myszkowski (CFO), Patrick O'Brien (General Counsel), Tracie Oliver (Insider), Adeoye Olukotun (Director), Javier San Martin (Insider), and William Waddill (Director). Learn More on Arrowhead Pharmaceuticals' active insiders.
Are insiders buying or selling shares of Arrowhead Pharmaceuticals?: In the last year, Arrowhead Pharmaceuticals insiders bought shares 2 times. They purchased a total of 2,000 shares worth more than $54,990.00. In the last year, insiders at the biotechnology company sold shares 20 times. They sold a total of 408,135 shares worth more than $13,514,007.79. The most recent insider tranaction occured on March, 20th when Director Hongbo Lu bought 1,000 shares worth more than $27,500.00. Insiders at Arrowhead Pharmaceuticals own 4.5% of the company. Learn More about insider trades at Arrowhead Pharmaceuticals.
Information on this page was last updated on 3/20/2024.

James C. Hamilton Insider Trading History at Arrowhead Pharmaceuticals

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
1/12/2024	Sell	7,940	$36.89	$292,906.60	210,851
1/5/2024	Sell	32,143	$35.18	$1,130,790.74	218,791
1/3/2024	Sell	6,300	$32.19	$202,797.00	175,934
6/30/2023	Sell	3,000	$35.53	$106,590.00	188,484
1/5/2023	Sell	13,803	$37.40	$516,232.20	191,484
1/3/2023	Sell	10,338	$38.38	$396,772.44	145,287
1/4/2022	Sell	19,375	$65.49	$1,268,868.75
1/14/2021	Sell	10,000	$81.29	$812,900.00	130,064
1/5/2021	Sell	19,375	$72.53	$1,405,268.75	171,200

James C. Hamilton Buying and Selling Activity at Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals Company Overview

Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases. It also develops ARO-MMP7 that is in Phase 1/2a clinical trial for treatment of idiopathic pulmonary fibrosis; ARO-DUX4 for the treatment of facioscapulohumeral muscular dystrophy; ARO-SOD1 for the potential treatment of amyotrophic lateral sclerosis; and ARO-C3, which is in Phase 1/2a clinical trial for the treatment of patients with various complement mediated or complement associated renal diseases. In addition, the company is involved in the development of JNJ-3989, which is in Phase 2 clinical trial to treat chronic hepatitis B virus infection; Olpasiran that is in Phase 3 clinical trial to reduce the production of apolipoprotein A; GSK-4532990 that is in phase 2 clinical trial to treat liver diseases; HZN-457, which is in phase 1 clinical trial to treat uncontrolled gout; and Fazirsiran that is in Phase 3 clinical trial for the treatment for liver disease associated with alpha-1 antitrypsin deficiency. Arrowhead Pharmaceuticals, Inc. has license and research collaboration agreements with Janssen Pharmaceuticals, Inc.; Takeda Pharmaceutical Company Limited; Horizon Therapeutics Ireland DAC; Amgen Inc.; and Glaxosmithkline Intellectual Property (No. 3) Limited. The company was founded in 2003 and is headquartered in Pasadena, California.

Today's Range

Now: $22.12

$21.72

$22.36

50 Day Range

MA: $28.12

$21.87

$36.08

2 Week Range

Now: $22.12

$20.67

$42.48

Volume

617,025 shs

Average Volume

845,266 shs

Market Capitalization

$2.74 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.71

The Best AI Stock to Own in the World Today is Trading for Just $25

From Banyan Hill Publishing | Ad

See how you can invest alongside him

James Hamilton Biography and Net Worth

What is James C. Hamilton's net worth?

How old is James C. Hamilton?

What is James C. Hamilton's salary?

How do I contact James C. Hamilton?

Has James C. Hamilton been buying or selling shares of Arrowhead Pharmaceuticals?

Who are Arrowhead Pharmaceuticals' active insiders?

Are insiders buying or selling shares of Arrowhead Pharmaceuticals?